Randomized ph. II Study to Explore Efficacy and Feasibility of Upfront Rotations Between SUNitinib and Everolimus vs Sequential Treatment of 1st lIne Sunitinib & 2nd Line EverolimuS Until Progression in Pats Met. Clear Cell Renal Cancer
Phase of Trial: Phase II
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Everolimus (Primary) ; Sunitinib (Primary)
- Indications Renal cancer
- Focus Therapeutic Use
- Acronyms SUNRISES
- 29 Sep 2017 Status changed from recruiting to discontinued.
- 18 Jul 2017 The trial has been Discontinued in Greece.
- 13 May 2017 This trial has been completed in Spain (end date: 8 May 2017).